Feedback / Questions
NKTR-0165 - Nektar Therap, Biolojic Design
https://www.globenewswire.com/news-release/2024/04/24/2868445/0/en/Biolojic-Design-Announces-that-Nektar-Therapeutics-Has-Exercised-Its-License-Option-to-Develop-an-AI-Designed-Agonistic-Antibody-Targeting-TNFR2-for-the-Treatment-of-Autoimmune-Dis.html
Apr 24, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next